ManagedCareCGM.com Presents: The Value of Continuous Glucose Monitoring during the COVID-19 Pandemic and New Era of Digital Healthcare

• Release Date: September 15, 2020
• Expiration Date: March 31, 2022
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Daniel DeSalvo, MD Assistant Professor Pediatric Endocrinologist Baylor College of Medicine Texas Children’s Hospital Click here for biography Jeffrey Dunn, PharmD, MBA (Formerly) Vice President, Clinical Strategy and Programs and Industry Relations Magellan Rx Management Click here for biography Troy Ross, MSM President & CEO Mid-America Coalition on Health Care Click here for biography

Target Audience

• This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Statement of Need/Program Overview 

Innovations in CGM technology have the promise of improved glucose control and quality of life. Several studies have demonstrated the safety, efficacy, and cost effectiveness of this technological revolution. The current COVID-19 pandemic has forced us to reconsider the ways in which effective diabetes management is delivered during these challenging times - both in the inpatient and outpatient setting. The availability of connected CGM data facilitates effective diabetes management remotely. Recently, the FDA has allowed for the use of real-time CGM (rtCGM) in hospital settings to support COVID-19 healthcare-related efforts during the current pandemic. Remote patient monitoring facilitates timely medical intervention and has the potential to limit staff exposure to the novel coronavirus and preserve vital personal protective equipment (PPE). This program will elucidate the burden of diabetes and describe multifaceted clinical and administrative strategies to promote quality care and manage costs while improving outcomes for affected plan members.

Educational Objectives 
After completing this activity, the participant should be better able to: 

• Describe the benefits of remote monitoring in the management of hospitalized patients with COVID-19 and dysglycemia
• Assess the value of rtCGM in improving quality of care and reducing societal health-costs in a new era of digital health
• Characterize the role of rtCGM as part of an employer-driven diabetes management strategy
• Identify appropriate benefit design strategies to reduce healthcare system burden and improve quality, clinical, and economic outcomes

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources (MER), National Hemophilia Foundation, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates these enduring materials for a maximum of 1.0 AMA PRA Category 1 Credit ^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Credit Designation
Medical Education Resources designates these continuing education activities for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
UAN: 0816-9999-20-142-H01-P.  
This activity is certified as Knowledge-based CPE.

Nursing Continuing Education

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Medical Education Resources is accredited as a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Credit Designation
These educational activities for 1.0 contact hour are provided by Medical Education Resources.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Dexcom. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period September 15, 2020 through March 15, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 70% or better and the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.